Baroreflex activation therapy in advanced heart failure therapy: insights from a real-world scenario.

Abstract

Baroreflex activation therapy (BAT) is an innovative treatment option for advanced heart failure (HFrEF). We analysed patients' BAT acceptance and the outcome of BAT patients compared with HFrEF patients solely treated with a guideline-directed medical therapy (GDMT) and studied effects of sacubitril/valsartan (ARNI). In this prospective study, 40 HFrEF patients (71±3years, 20% female) answered a questionnaire on the acceptance of BAT. Follow-up visits were performed after 3, 6, and 12months. Primary efficacy endpoints included an improvement in QoL, NYHA class, LVEF, HF hospitalization, NT-proBNP levels, and 6MHWD. Twenty-nine patients (73%) showed interest in BAT. Ten patients (25%) opted for implantation. BAT and BAT+ARNI patients developed an increase in LVEF (BAT +10%, P-value (P)=0.005*; BAT+ARNI +9%, P=0.049*), an improved NYHA class (BAT -88%, P=0.014*, BAT+ARNI -90%, P=0.037*), QoL (BAT +21%, P=0.020*, BAT+ARNI +22%, P=0.012*), and reduced NT-proBNP levels (BAT -24%, P=0.297, BAT+ARNI -37%, P=0.297). BAT HF hospitalization rates were lower (50%) compared with control group patients (83%) (P=0.020*). Although BAT has generated considerable interest, acceptance appears to be ambivalent. BAT improves outcome with regard to LVEF, NYHA class, QoL, NT-proBNP levels, and HF hospitalization rates. BAT+ARNI resulted in more pronounced effects than ARNI alone.